IP Model and Costs

All MedChem Australia projects will run collaboratively with shared IP, shared benefits, and subsidised costs as the default model

As the Project Provider(s) and MedChem Australia will be joint contributors to the creation of new intellectual property (IP), newly created IP will be owned jointly by the parties. Shared benefits (e.g revenue share) will also be negotiated. Decisions around which organisation takes on the commercialisation lead role will be negotiated in good faith at the appropriate time.

To break down the medicinal chemistry capability barrier, a hallmark of the MedChem Australia model is the provision of an 80% subsidy to offset the total MedChem Australia project costs. The 80% subsidy will be applied to already low “internal” FTE rates. Cost examples are illustrated below. Additional support such as supervision and senior leadership input will be provided to projects in-kind

MedChem Australia appreciates that for some organisations, a shared IP model may not be feasible. Under special circumstances, applicants may negotiate changes to the IP model, on a case-by-case basis. Please contact MedChem Australia directly to discuss further. As MedChem Australia is not a separate legal entity, the formal contractual arrangements will be entered into between the successful applicant’s organisation and the MedChem Australia Node that the project has been allocated to.

Project provider IP Model Cost model
Default model
  • Australian University, Research Institute, small company
  • Shared new IP
  • Shared benefits (revenue share) negotiated
  • Commercialisation lead negotiated in good faith at appropriate time.
  • Subsidised cost model (project provider receives 80% subsidy from “internal” FTE rates)
Negotiated model
  • E.g. For-profit SMEs
  • IP assigned to SME
  • Shared benefits (revenue share)
  • Additional obligations including shared project information and shared recognition
  • Subsidised cost model

What are the expected costs?

MedChem Australia provides an 80% subsidy, meaning that successful applicants will contribute 20% of the total MedChem Australia project costs. Estimated costs, based on the project and resource plan, will be agreed to in the project agreement. Additional support such as supervision and senior leadership input will be provided to projects in-kind

 

Resource Level Example resource allocation
(exact resource allocations will be dependent upon project requirements)
 Example cost to the successful applicant
Level A 1 Medicinal Chemist FTE + consumables + DMPK / year ~$30 – 43K including consumables & DMPK
Level B 2.5 Medicinal Chemistry FTE + consumables + DMPK / year $75 – 109K including consumables & DMPK
Level C 4 Medicinal Chemistry FTE + consumables + DMPK / year $120 – 174K including consumables & DMPK